THE BRAIN TUMOUR CHARITY

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +48.4%

  £3,487,000 → £5,176,000

• Net assets

  +3%

  £8,531,000 → £8,788,000

• Employees

  +1.7%

  116 → 118

• Wages

  +7.3%

  £4,304,000 → £4,617,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. THE BRAIN TUMOUR CHARITY 2013-05-10 → present
2. TBTF 2012-10-24 → 2013-05-10

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Menzies LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.”

Group structure

1. THE BRAIN TUMOUR CHARITY · parent
   1. Medli Health Holding Limited 100% · England and Wales · Intellectual property commercialisation (holding company)
   2. Medli Health Limited 100% · England and Wales · Intellectual property commercialisation
   3. Acquist Data Holdings Limited 100% · England and Wales · Intellectual property commercialisation (holding company)
   4. Acquist Data Limited 100% · England and Wales · Intellectual property commercialisation
   5. TBTC Trading Ltd 100% · England and Wales · Retailing

Significant events

• “Landmark approval of the combination of dabrafenib and trametinib for treating children diagnosed with BRAF-mutated gliomas in May 2024, the first positive change in brain tumour treatment in a generation.”
• “First-ever Translational Award launched to move breakthroughs out of labs and make them available to the community.”
• “First-ever Quality-of-Life Award launched and awarded four Quality-of-Life grants totalling £380,000.”
• “Two Future Leaders (Dr Tyler Miller and Dr Ángel Álvarez-Prado) established their own research labs in 2024/25.”
• “Open letter calling for a National Brain Tumour Strategy handed in at UK parliaments in April.”
• “Campaign launched in October encouraging people to write to their MP to discuss a National Brain Tumour Strategy, resulting in over 3,400 participants.”
• “Rare Cancers Bill passed its second reading after an emotional debate in Parliament.”
• “A record-breaking year for fundraising, raising £15.3m in 2024/25, exceeding target by £300k.”
• “Wickes partnership raised £2m over two years and increased charity profile.”
• “TCS London Marathon team raised £820,000.”
• “Piloted a door-to-door fundraising campaign, gaining almost 600 new donors.”
• “Better Safe Than Tumour advert screened to an estimated 1.6m cinemagoers.”
• “Decision made in August 2024 to terminate the BRIAN application and database to focus resources on other activities.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.